Table 1 Characteristics of multiple myeloma randomized clinical trials that reported +1q.
From: Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review
Study Characteristics | No. of studies reporting +1q (%) | No. of studies not reporting +1q (%) |
|---|---|---|
Frontline or consolidation/maintenance | 20 (71) | 60 (63) |
Relapsed/refractory | 8 (29) | 36 (37) |
Multinational | 12 (43) | 53 (55) |
Limited to a single country except the US | 12 (43) | 25 (26) |
Limited to the US | 4 (14) | 18 (19) |
Year 2012–2015 | 4 (14) | 37 (39) |
Year 2016–2019 | 11 (38) | 49 (51) |
Year 2020–2022 | 14 (48) | 10 (10) |
